



October 29, 2026

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
--	---

Sub: Outcome of Board Meeting of ANLON HEALTHCARE LIMITED (“Company”)

Respected Sir/Madam,

Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, October 29, 2026 at the Registered Office of the Company inter alia considered and approved the following matters:

1. Unaudited Standalone and Consolidated Financial Results of the Company as set out in compliance with Indian Accounting Standards ("IND AS") for the quarter and half year ended September 30, 2026; together with the Limited Review Report of the Auditor's thereon. (Enclosed herewith)

Meeting commenced on 03:00 p.m. IST and concluded on 04:00 p.m. IST.

You are requested to take the above information on your record.

Thanking You.

For ANLON HEALTHCARE LIMITED

Rasadia

Punitkumar

Rameshbhai

Digitally signed by Rasadia Punitkumar Rameshbhai
DN: c=IN, o=Personal, ou=4298,
serialNumber=13964632625247286186, email=dyt@P1,
2.5.4.20=a0055c4c1c1389f6122af9354077137a4a1,
ec074ed223ac0e8dc8264a5a2, postalCode=360005,
st=Gujarat,
serialNumber=90675666c809e74b4ab895e7d3c841c,
cn=Rasadia Punitkumar Rameshbhai,
Date: 2026.10.29 17:21:36 +05'30'

PUNITKUMAR RASADIA

MANAGING DIRECTOR

DIN: 06696258

ANLON HEALTHCARE LIMITED

CIN No.: L24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


**Review Report to
The Board of Directors
Anlon Healthcare Limited**

- (1) We have reviewed the accompanying statement of unaudited standalone financial results of Anlon Healthcare Limited (the 'Company') for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
- (2) This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- (3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- (4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For, R V D & Co
Chartered Accountants
ICAI Firm Registration No 143936W**

**Date: October 29, 2026
Place: Rajkot**


**Kaushal V. Dave
(Partner)
Membership No 174550
UDIN: 26174550YHVDHM2107**



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

Anlon Healthcare Limited
L24230GJ2013PLC077543
Registered Office: 101/102, Silver Coin Complex, Opposite Crystal Mall, Kalawad Road, Rajkot – 360005, Gujarat, India
Standalone Financial Result for the period ended on 30-9-2026

Rs. in Lakhs

Sr No	Particulars	Quarter Ended			Half year ended		Year Ended
		30-9-2026	30-6-2026	30-9-2025	30-9-2026	30-9-2025	31 March 2026
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	Income						
	Revenue From Operations	6,045.46	3,097.56	5,220.13	9,143.02	8,549.85	17,649.87
	Other Income	2.54	5.96	2.72	8.50	3.89	25.39
	Total Income (I)	6,048.00	3,103.52	5,222.85	9,151.52	8,553.74	17,675.26
II	Expenses						
	Cost of materials consumed	2,518.60	2,694.05	4,082.97	5,212.65	7,042.45	12,976.38
	Changes in inventories of finished goods, Stock in Trade and work in	1,555.44	(789.16)	(787.17)	766.28	(1,324.35)	(1,691.69)
	Employee benefits expense	213.66	152.07	106.17	365.73	228.66	525.12
	Finance costs	93.74	96.36	83.80	190.10	165.85	435.29
	Depreciation and amortization expense	60.17	65.79	45.21	125.96	87.89	136.31
	Other expenses	309.94	294.04	447.19	603.98	608.15	1,226.28
	Total expenses (II)	4,751.55	2,513.15	3,978.17	7,264.70	6,808.65	13,607.69
III	Profit/(loss) before tax (I-II)	1,296.45	590.37	1,244.68	1,886.82	1,745.09	4,067.57
IV	Tax expenses						
	Current tax	296.75	152.39	315.85	449.14	463.76	1,140.03
	Deferred tax	195.03	(41.73)	(2.90)	153.30	(5.09)	146.72
	Total Tax expense (IV)	491.78	110.66	312.95	602.44	458.67	1,286.75
V	Profit/(loss) after tax for the period (III-IV)	804.67	479.71	931.73	1,284.38	1,286.42	2,780.82
VI	Other Comprehensive Income						
	OCI that will not be reclassified to P&L	4.68	(2.31)	-	2.37	-	(6.79)
	OCI Income tax of items that will not be reclassified to P&L	(1.22)	0.58	-	(0.64)	-	1.70
	Total Other Comprehensive Income (VI)	3.46	(1.73)	-	1.73	-	(5.09)
VII	Total Comprehensive Income for the period (V+VI)	808.13	477.98	931.73	1,286.11	1,286.42	2,775.73
VIII	Details of Equity Share Capital						
	Paid-Up Equity Share Capital (Number in Lakhs)	10,630.30	10,630.30	5,315.15	10,630.30	5,315.15	5,315.15
	Face Value of Equity Share Capital (Per Value)	2.00	2.00	10.00	2.00	10.00	10.00
	Other Equity						
IX	Earnings per equity share						
	Basic	0.15	0.09	0.18	0.24	0.24	0.59
	Diluted	0.15	0.09	0.18	0.24	0.24	0.59

 For and on behalf of Board of Directors,
 Anlon Healthcare Limited
 (CIN: L24230GJ2013PLC077543)

 Punittkumar R. Rasadia
 Managing Director
 6696258

 Place: Rajkot
 Date: 29.10.2026

 SIGNED FOR IDENTIFICATION BY
 R V D & Co.
 Chartered Accountants
 FRN 143936W

 Date: 29/10/2026
 Place: Rajkot

Anlon Healthcare Limited

L24230GJ2013PLC077543


Registered Office: 101/102, Silver Coin Complex, Opposite Crystal Mall, Kalawad Road, Rajkot – 360005, Gujarat, India

Standalone Balance Sheet as at 30-9-2026

Rs. in Lakhs

Particulars	As at 30 September 2026 Un - Audited	As at 31 March 2026 Audited
ASSETS		
Non-current assets		
Property, Plant and Equipment	4,176.97	4,036.29
Capital work in progress	136.23	-
Financial Assets		
Investments	1,475.39	1,016.52
Other non current assets	145.38	694.60
Total Non-current Assets	5,933.97	5,747.41
Current assets		
Inventories	9,263.78	7,558.95
Financial Assets		
Investments	71.92	1.00
Trade receivables	11,104.08	10,417.14
Cash and cash equivalents	451.99	341.29
Loans	870.74	19.46
Other current assets	6,104.18	7,635.25
Total Current Assets	27,866.69	25,973.09
Total Assets	33,800.66	31,720.50
EQUITY and LIABILITIES		
Equity Share Capital	10,630.30	5,315.15
Other Equity	11,621.57	15,662.12
Total Equity	22,251.87	20,977.27
Non-current liabilities		
Financial Liabilities		
Borrowings	454.32	248.06
Provisions	66.25	36.68
Deferred tax liabilities net	521.46	367.52
Total Non-current liabilities	1,042.03	652.26
Current liabilities		
Financial Liabilities		
Borrowings	5,256.96	4,311.87
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	69.62	7.66
- total outstanding dues of others	2,613.56	3,934.64
Other current liabilities	786.41	632.50
Provisions - current	210.07	60.63
Current Tax Liabilities, net	1,570.14	1,143.67
Total Current liabilities	10,506.76	10,090.97
Total liabilities	11,548.79	10,743.23
Total Equity and Liabilities	33,800.66	31,720.50

For and on behalf of Board of Directors,
Anlon Healthcare Limited
(CIN: L24230GJ2013PLC077543)


Punifkumar R. Rasadia
Managing Director
6696258



Place: Rajkot
Date: 29.10.2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date: 29/10/2026
Place: Rajkot

Anlon Healthcare Limited

L24230GJ2013PLC077543

Registered Office: 101/102, Silver Coin Complex, Opposite Crystal Mall, Kalawad Road, Rajkot – 360005, Gujarat, India

Standalone Cash Flow Statement for the period ended on 30-9-2026

Rs. in Lakhs

Particulars	For Period ended 30 September 2026	For Period ended 30 September 2025	For Year ended 31 March 2026
	Un Audited	Un Audited	Audited
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit for the Period / Year	1,284.38	1,286.42	2,780.82
<u>Adjustments for:</u>			
Depreciation and amortisation	125.96	87.89	136.31
Provision for Gratuity Expenses & Leave Encashments	37.92	-	-
Provision for CSR Liability	57.47	-	-
(Gain)/Loss on investments measured at fair value through profit and loss	-	-	-
Provision for Income tax	602.44	458.66	1,286.75
Finance Cost	190.10	168.32	435.29
Interest Income	(1.51)	-	(20.86)
Operating profit before working capital changes	2,296.76	2,001.29	4,618.31
Adjustment for (increase) / decrease in operating assets			
Trade receivables	(686.94)	(3,245.27)	(2,917.27)
Loans & Advances	(851.28)	(8.88)	208.49
Other financial assets	-	(1,692.96)	138.04
Inventories	(1,704.83)	(626.81)	(2,532.64)
Other assets	2,080.29	(3,236.60)	(5,609.80)
Adjustment for (Increase) / decrease in operating liabilities			
Trade payables	(1,259.12)	(308.54)	1,977.94
Employee benefit obligation	-	-	-
Other Liabilities	153.91	(666.56)	199.03
Provisions	85.99	460.84	35.66
Cash generated from operations	114.78	(7,323.49)	(3,882.24)
Income tax paid (net)	(22.67)	(463.76)	(753.57)
Net cash generated by operating activities	92.11	(7,787.25)	(4,635.81)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(402.87)	(2.92)	(1,890.70)
Purchase of other Investment	(529.79)	(1,743.17)	(926.61)
Interest received	1.51	-	20.86
Net cash (used in) / generated by investing activities	(931.15)	(1,746.09)	(2,796.45)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from short term borrowings	945.08	697.63	1,492.14
Proceeds from long term borrowings	206.26	(749.86)	(3,587.64)
Finance cost	(190.10)	(168.32)	(435.29)
Issue of Equity Shares	(11.51)	12,103.00	10,159.37
Net cash used in financing activities	949.73	11,882.45	7,628.58
Net increase / (decrease) in cash and cash equivalents	110.69	2,349.11	196.32
Cash and cash equivalents at the beginning of the year	341.29	144.96	144.96
Exchange gain loss on Cash and cash equivalents	-	-	-
Cash and cash equivalents at the end of the year	451.98	2,494.07	341.28

Particulars	As at 30 September 2026	As at 30 September 2025	As at 31 March 2026
Reconciliation of Cash and Cash Equivalents with Balance Sheet:			
Cash and cash equivalents includes			
Cash on hand	423.34	228.01	327.60
Balances with Banks	28.66	2,266.06	13.69

For and on behalf of Board of Directors,

Anlon Healthcare Limited

(CIN: L24230GJ2013PLC077543)

Panitkumar R. Rasadia

Managing Director

6696258



Place: Rajkot

Date: 29.10.2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date: 29/10/2026

Place : Rajkot

1 Corporate information

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

2 Basis of Preparation

The Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The standalone financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

3 Segment Reporting

Anlon Healthcare Limited is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

4 The Status of investor complaints received by the company is as follows :

During the second quarter of FY 2026–27, the Company received one complaint from an investor, which remains pending as of the reporting date

5 List of Group Companies or Subsidiary company

- (1) Bizotic Lifescience Private Limited
- (2) Apiqo Organics Private Limited.
- (3) Anlon Medicos Private Limited (formerly known as Remember India Health Links Private Limited)
- (4) Anlon Biologics Private Limited
- (5) Anlon Medicare Private Limited
- (6) Anlon Healthcare Nigeria Limited

6 The above financial results of Anlon Healthcare Limited (the "Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 29, 2026, respectively

7 The figures for the previous periods have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current period's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current period's financial statements.

8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel, Packing Material, Factory Electricity Expenses, Freight Inward, Advertisement Expenses, Canteen and -Import Duty Expenses Etc

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date 29/10/2026
Place : Rajkot

Place: Rajkot
Date: 29.10.2026

For and on behalf of Board of Directors,
Anlon Healthcare Limited


Punitkumar R. Rasadia
Managing Director



Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Anlon Healthcare Limited**

- (1) We have reviewed the accompanying statement of unaudited Consolidated financial results of Anlon Healthcare Limited (the 'Company') for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
- (2) This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- (3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

- (4) The Statement includes the interim financial results of the following entities:

Name of the Entity	Relationship
Anlon Healthcare Limited	Holding Company
Apiqo Organics Private Limited	Subsidiary Company
Bizotic Lifescience Private Limited	Subsidiary Company
Anlon Medicos Private Limited (formerly known as Remember India Health Links Private Limited)	Subsidiary Company
Anlon Biologics Private Limited	Subsidiary Company
Anlon Medicare Private Limited	Subsidiary Company



Other Matters

- (5) The Statement includes the unaudited interim financial results and other unaudited financial information, in respect of:
- (i) Five subsidiaries, whose unaudited interim financial results and other unaudited financial information include total revenue (before consolidation adjustments) of ₹5320.04 lakhs, total net Profit after tax (before consolidation adjustments) of ₹916.75 lakhs, total comprehensive Profit (before consolidation adjustments) of ₹916.75 lakhs for the quarter ended September 30, 2026, as considered in the Statement. These unaudited financial results and financial information have been approved and furnished to us by the Management of the Holding Company and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on such unaudited financial results and financial information.

For, R V D & Co
Chartered Accountants
ICAI Firm Registration No 143936W

Date: October 29, 2026
Place: Rajkot



Kaushal V. Dave
(Partner)
Membership No 174550
UDIN: 26174550RNOFFY6229



Rs. in Lakhs (Unless stated otherwise)

Sr No	Particulars	Quarter Ended		30-09-2025	Half year ended		Year Ended 31 March 2026
		30-09-2026	30-06-2026		30-09-2026	30-09-2025	
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	Income						
	Revenue From Operations	10,560.97	8,756.27	5,220.13	19,317.24	8,549.85	19,190.70
	Other Income	4.53	5.96	2.72	10.49	3.89	25.54
	Total Income (I)	10,565.50	8,762.23	5,222.85	19,327.73	8,553.74	19,216.24
II	Expenses						
	Cost of materials consumed	4,868.68	7,303.61	4,082.97	12,172.29	7,042.45	16,925.09
	Changes in inventories of finished goods, Stock in Trade and work in	2,418.83	(695.55)	(787.17)	1,723.28	(1,324.35)	(4,420.85)
	Employee benefits expense	259.42	194.65	106.17	454.07	228.66	554.04
	Finance costs	86.18	92.46	83.80	178.64	165.85	374.07
	Depreciation and amortization expense	95.02	106.60	45.21	201.62	87.89	152.41
	Other expenses	489.92	394.47	447.19	884.39	608.15	1,380.76
	Total expenses (II)	8,218.05	7,396.24	3,978.17	15,614.29	6,808.65	14,965.52
III	Profit/(loss) before tax (I-II)	2,347.45	1,365.99	1,244.68	3,713.44	1,745.09	4,250.72
IV	Tax expenses						
	Current tax	592.07	349.30	315.85	941.37	463.76	1,180.27
	Deferred tax	37.58	188.55	(2.90)	226.13	(5.09)	161.64
	Total Tax expense (IV)	629.65	537.85	312.95	1,167.50	458.67	1,341.91
V	Profit/(loss) after tax for the period (III-IV)	1,717.80	828.14	931.73	2,545.94	1,286.42	2,908.81
VI	Other Comprehensive Income						
	OCI that will not be reclassified to P&L	4.89	(2.52)	-	2.37	-	(6.79)
	OCI Income tax of items that will not be reclassified to P&L	(1.27)	0.63	-	(0.64)	-	1.70
	Total Other Comprehensive Income (VI)	3.62	(1.89)	-	1.73	-	(5.09)
VII	Total Comprehensive Income for the period (V+VI)	1,721.42	826.25	931.73	2,547.67	1,286.42	2,903.72
VIII	Profit/(loss) after tax for the period (III-IV) attributable to:						
	-Owners of the company	1,336.57	666.21	931.73	2,002.78	1,286.42	2,851.38
	-Non-Controlling Interests	381.23	161.93	-	543.16	-	57.43
		1,717.80	828.14	931.73	2,545.94	1,286.42	2,908.81
IX	Total Other Comprehensive Income (VI) attributable to:						
	-Owners of the company	3.62	(1.89)	-	1.73	-	(5.09)
	-Non-Controlling Interests	-	-	-	-	-	-
		3.62	(1.89)	-	1.73	-	(5.09)
X	Total Comprehensive Income for the period (V+VI) attributable to:						
	-Owners of the company	1,340.19	664.32	931.73	2,004.51	1,286.42	2,846.29
	-Non-Controlling Interests	381.23	161.93	-	543.16	-	57.43
		1,721.42	826.25	931.73	2,547.67	1,286.42	2,903.72
XI	Details of Equity Share Capital						
	Paid-Up Equity Share Capital (Number in Lakhs)	10,630.30	10,630.30	5,315.15	10,630.30	5,315.15	5,315.15
	Face Value of Equity Share Capital (Per Value)	2.00	2.00	10.00	2.00	10.00	10.00
	Other Equity						
XII	Earnings per equity share						
	Basic	0.32	0.16	0.18	0.48	0.24	0.61
	Diluted	0.32	0.16	0.18	0.48	0.24	0.61

For and on behalf of Board of Directors,
Anlon Healthcare Limited
(CIN: L24230GJ2013PLC077543)


Punithkumar R. Rasadia
Managing Director
6696258



Place: Rajkot
Date : 29.10.2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date: 29.10.2026
Place : Rajkot

Anlon Healthcare Limited
L24230GJ2013PLC077543

Registered Office 101/102, Silver Coin Complex, Opposite Crystal Mall, Kalawad Road, Rajkot – 360005, Gujarat, India
Consolidated Balance Sheet as at 30-09-2026

Rs. in Lakhs (Unless stated otherwise)

Particulars	As at 30 Sept 2026 Un-Audited	As at 31 March 2026 Audited
ASSETS		
Non-current assets		
Property, Plant and Equipment	7,853.01	5,771.36
Capital work in progress	136.23	-
Goodwill	88.15	4.79
Financial Assets		
Investments	-	97.89
Other non current assets	309.29	696.44
Total Non-current Assets	8,386.68	6,570.48
Current assets		
Inventories	12,021.09	11,316.34
Financial Assets		
Investments	72.92	1.00
Trade receivables	14,275.26	10,367.77
Cash and cash equivalents	725.52	436.59
Loans	98.85	19.46
Other financial assets	-	-
Other current assets	9,691.26	8,684.87
Total Current Assets	36,884.90	30,826.03
Total Assets	45,271.58	37,396.51
EQUITY and LIABILITIES		
Equity Share Capital	10,630.30	5,315.15
Other Equity	15,109.09	17,707.71
Total Equity	25,739.39	23,022.86
Non controlling interests	3,816.31	2,456.56
Non-current liabilities		
Financial Liabilities		
Borrowings	1,061.58	609.37
Provisions	66.24	36.68
Deferred tax liabilities net	72.70	514.47
Total Non-current liabilities	1,200.52	1,160.52
Current liabilities		
Financial Liabilities		
Borrowings	6,167.33	3,755.90
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	69.62	7.66
- total outstanding dues of others	3,006.44	4,211.57
Other current liabilities	2,938.00	1,395.54
Provisions - current	210.87	66.06
Current Tax Liabilities, net	2,123.10	1,319.84
Total Current liabilities	14,515.36	10,756.57
Total liabilities	15,715.88	11,917.09
Total Equity and Liabilities	45,271.58	37,396.51

For and on behalf of Board of Directors,
Anlon Healthcare Limited
(CIN: L24230GJ2013PLC077543)

Place: Rajkot
Date : 29.10.2026

Punitkumar R. Rasadia
Managing Director
6696258

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date: 29/10/2026
Place : Rajkot

Anlon Healthcare Limited
L24230GJ2013PLC077543

Registered Office 101/102, Silver Coin Complex, Opposite Crystal Mall, Kalawad Road, Rajkot – 360005, Gujarat, India
Consolidated Cash Flow Statement for the period ended on 30-09-2026

Rs. in Lakhs

Particulars	For Period ended	For Period ended	For Year ended
	30 September 2026	30 September 2025	31 March 2026
	Un Audited	Un Audited	Audited
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit for the year	2,545.94	1,286.42	2,908.81
Adjustments for:			
Depreciation and amortisation	201.62	87.89	152.41
Provision of Gratuity and Leave Encashments	43.30	-	25.77
Provision for CSR Liability	57.47	-	-
(Gain)/Loss on investments measured at fair value through profit and loss	-	-	-
Provision for Income tax	1,167.50	458.66	1,341.91
Finance Cost	178.64	168.32	374.06
Interest Income	(3.51)	-	(20.97)
Operating profit before working capital changes	4,190.96	2,001.29	4,781.99
Adjustment for (increase) / decrease in operating assets			
Trade receivables	(3,907.49)	(3,245.27)	(2,867.90)
Loans & Advances	(79.39)	(8.88)	208.49
Other financial assets	-	(1,692.96)	138.04
Inventories	(704.75)	(626.81)	(6,290.03)
Other assets	(619.24)	(3,236.60)	(6,661.26)
Trade payables	(1,143.17)	(308.54)	2,254.88
Other Liabilities	1,542.47	(666.56)	962.06
Provisions	64.47	460.84	15.32
Cash generated from operations	(656.14)	(7,323.49)	(7,458.41)
Income tax paid (net)	(138.11)	(463.76)	(485.59)
Net cash generated by operating activities	(794.25)	(7,787.25)	(7,944.00)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(2,798.62)	(2.92)	(3,641.88)
Purchase of Goodwill	(83.36)	-	(4.79)
Purchase of other Investment	25.97	(1,743.17)	(7.98)
Interest received	3.51	-	20.97
Net cash (used in) / generated by investing activities	(2,852.50)	(1,746.09)	(3,633.68)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from short term borrowings	2,411.42	697.63	936.17
Proceeds from long term borrowings	452.21	(749.86)	(3,226.33)
Finance cost	(178.64)	(168.32)	(374.06)
Issue of Equity Shares	-	12,103.00	12,134.40
Issue of Shares by Subsidiary Company	434.10	-	-
Non controlling interests	816.59	-	2,399.13
Share Issue Expenses	-	-	-
Net cash used in financing activities	3,935.68	11,882.45	11,869.31
Net increase / (decrease) in cash and cash equivalents	288.93	2,349.11	291.63
Cash and cash equivalents at the beginning of the year	436.59	144.96	144.96
Cash and cash equivalents at the end of the year	725.52	2,494.07	436.59

Particulars	As at 30 Sept 2026	As at 30 Sept 2025	As at 31 Mar 2026
Reconciliation of Cash and Cash Equivalents with Balance Sheet:			
Cash and cash equivalents includes			
Cash on hand	507.34	228.01	358.24
Balances with Banks	218.19	2,266.06	78.35

For and on behalf of Board of Directors,
Anlon Healthcare Limited
(CIN: L24230GJ2013PLC077543)

Punitkumar R. Rasadia
Managing Director
6696258



Place:Rajkot
Date :29.10.2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date:29/10/2026
Place : Rajkot

Anlon Healthcare Limited

L24230GJ2013PLC077543

Notes to the Consolidated Financial Result for the period ended on 30-09-2026

1 Corporate information

The consolidated financial statements comprise financial statements of Anlon Healthcare Limited (the "Company") and its subsidiaries (collectively the "Group") for the period ended September 30, 2026

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

2 Basis of Preparation

The Consolidated Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The Consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The Consolidated financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

3 Segment Reporting

Anlon Healthcare Limited and its Subsidiaries is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

4 The Status of investor complaints received by the company is as follows :

During the second quarter of FY 2026–27, the Company received one complaint from an investor, which remains pending as of the reporting date

5 List of Group Company or Subsidiary company

- (1) Bizotic Lifescience Private Limited
- (2) Apiqo Organics Private Limited.
- (3) Anlon Medicos Private Limited (formerly known as Remember India Health Links Private Limited)
- (4) Anlon Biologics Private Limited
- (5) Anlon Medicare Private Limited
- (6) Anlon Healthcare Nigeria Limited*


**Anlon Healthcare Nigeria Limited has not undertaken any transactions to date. Further, payment for the shares is yet to be made, and no shares have been allotted. Accordingly, considering the absence of control over the entity, Anlon Healthcare Nigeria Limited has not been consolidated in the financial statements*

6 The figures for the previous periods have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current period's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current period's financial statements.

7 Other Expenses includes operational, statutory, and administrative expenses Power Fuel, Packing Material, Factory Electricity Expenses, Freight Inward, Advertisement Expenses, Canteen and -Import Duty Expenses Etc

For and on behalf of Board of Directors,
Anlon Healthcare Limited

Place: Rajkot
Date : 29.10.2026


Punit Kumar R. Rasadia
Managing Director



SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date: 29/10/2026
Place : Rajkot